{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-147869","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2021-12-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.687209+00:00","generated_at":"2026-06-28T02:29:21.202845+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada reports Q3 2021 net loss $14.4M and closes $208.7M IPO","bullets":["Net loss for Q3 2021 was $14.4M vs $7.0M in Q3 2020; R&D expense $10.5M, G&A $3.9M.","Closed upsized IPO in November, raising $208.7M gross ($190.9M net) at $20.00 per share.","IPO included full exercise of underwriters' option for 1.36M additional shares; total shares issued 10.44M.","Cash position as of Sep 30, 2021 was $122.2M, excluding IPO proceeds; post-IPO cash significantly strengthened.","Lead candidate ENTR-601-44 for DMD advancing toward initial clinical data; DM1 program entering development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-147869","json":"https://secwatch.observer/filing/0001104659-21-147869.json","markdown":"https://secwatch.observer/filing/0001104659-21-147869.md","text":"https://secwatch.observer/filing/0001104659-21-147869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/0001104659-21-147869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000110465921147869/tm2134805d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T02:29:21.202845+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}